<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <style type="text/css">

 p.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoHeading9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	text-indent:.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;
        }
p.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
a:link
	{color:blue;
	text-decoration:underline;
	text-underline:single;
        }
p.MsoHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	tab-stops:center 3.0in right 6.0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:27.0pt;
	text-align:justify;
	text-indent:-27.0pt;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
    </style>
</head>
<body>

    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoHeading9" style="margin:0in;margin-bottom:.0001pt;text-indent:0in">
        <span style="font-size:11.0pt">RE:<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>COLLABORATION AS A <st1:personname w:st="on">GIPAP</st1:PersonName> 
        QUALIFYING INSTITUTION/PHYSICIAN</u><o:p></o:p></span></p>
    <p class="MsoNormal">
        <o:p>&nbsp;</o:p></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt">The Max 
        Foundation: Background &amp; Services<o:p></o:p></span></b></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt">The Max Foundation (TMF) is a 
        US-based non-profit cancer organization with international focus. TMF is 
        dedicated to helping patients with leukaemia and blood-related cancers worldwide 
        by facilitating access to treatment and providing care and support for those who 
        have limited access to resources.<span style="mso-spacerun:yes">&nbsp; </span>
        TMF was established in 1997 in honour of the spirit and life of Maximiliano 
        “Max” Rivarola, who fought chronic myeloid leukaemia (CML) with outstanding 
        courage and grace. TMF provides the following services to patients and care 
        providers worldwide:<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l7 level1 lfo6;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Patient group facilitation <o:p></o:p></span>
    </p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l7 level1 lfo6;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Emotional support &amp; counselling<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l7 level1 lfo6;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Information about treatment options<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l7 level1 lfo6;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Referrals to services, resources, and clinical trials<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l7 level1 lfo6;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Facilitation of access to treatment including drug donations, patient assistance 
        programs, and helping patients navigate reimbursement for treatment through 
        their healthcare system<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <b style="mso-bidi-font-weight:normal"><span lang="EN-GB" 
            style="font-size:11.0pt">The Max Foundation &amp; Glivec International Patient 
        Assistance Program<o:p></o:p></span></b></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt">TMF is a partner in the 
        administration of the Glivec International Patient Assistance Program (GIPAP), a 
        program of Novartis Pharma AG. GIPAP was established by Novartis to enable 
        patients diagnosed with either <st1:city w:st="on"><st1:place w:st="on">
        Philadelphia</st1:place></st1:City>
        chromosome–positive chronic myeloid leukemia (CML) or metastatic malignant 
        gastrointestinal stromal tumors (GIST) to have access to Glivec<sup>® </sup>a 
        drug for a life-threatening disease. <o:p></o:p></span>
    </p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <b style="mso-bidi-font-weight:normal"><span lang="EN-GB" 
            style="font-size:11.0pt">Novartis gives Glivec at no cost to patients who:<o:p></o:p></span></b></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l4 level1 lfo7;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">Are 
        residents of countries where GIPAP is available<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l4 level1 lfo7;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">Have 
        been diagnosed with CML or GIST<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l4 level1 lfo7;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">Are 
        not insured or reimbursed<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l4 level1 lfo7;tab-stops:list .5in">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">Have 
        no other financial recourse (cannot afford to pay for treatment with Glivec)<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-bottom:0in;margin-bottom:.0001pt;
text-align:left">
        <b style="mso-bidi-font-weight:normal"><span lang="EN-GB" 
            style="font-size:11.0pt">As partners in the administration of GIPAP TMF:<o:p></o:p></span></b></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:39.1pt;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l3 level1 lfo8;tab-stops:list 39.1pt">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Accepts and reviews applications for GIPAP<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:39.1pt;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l3 level1 lfo8;tab-stops:list 39.1pt">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">Has 
        the sole and final responsibility for processing and assessing patients’ 
        eligibility for GIPAP<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:39.1pt;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l3 level1 lfo8;tab-stops:list 39.1pt">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Follows up on patients’ applications and re-evaluations for GIPAP<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:39.1pt;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l3 level1 lfo8;tab-stops:list 39.1pt">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Provides emotional support, information, and referral assistance to patients<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:39.1pt;margin-bottom:.0001pt;text-align:left;
text-indent:-.25in;mso-list:l3 level1 lfo8;tab-stops:list 39.1pt">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Provides information concerning adverse events to Novartis for reporting to 
        Health Authorities as required<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:21.1pt;margin-bottom:.0001pt;text-align:left">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt">
        Institutions/Physicians:<span style="mso-spacerun:yes">&nbsp; </span>Partners in 
        GIPAP<o:p></o:p></span></b></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">You have been identified as one of the leading 
        physicians/institutions in the treatment of CML and/or GIST in your country. The 
        local Novartis Country Pharma Organization (<st1:personname
w:st="on">CPO</st1:PersonName>) or Axios (where applicable) in collaboration with TMF is 
        responsible for identifying and qualifying leading medical centers, charity 
        organizations, and/or physicians, as the case may be
        <i style="mso-bidi-font-style:normal">(together the “<st1:personname w:st="on">GIPAP</st1:PersonName>
        Qualified Institution”) </i>in a <st1:personname w:st="on">GIPAP</st1:PersonName>
        country to work with the patients. As such, this document sets forth a 
        collaborative agreement between TMF and you for the administration of GIPAP, 
        with the goal of reaching resource poor patients internationally by facilitating 
        the donation of Glivec to patients who fulfill all program qualifications. A 
        desired outcome of our collaboration is to provide eligible patients access to 
        Glivec treatment following the highest quality control and safety standards.<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">The local Novartis 
        <st1:personname w:st="on">CPO</st1:PersonName> (or Axios, where applicable)</span><span 
            style="font-size:11.0pt"> is responsible for <span style="color:black">
        coordinating the necessary drug logistics and distribution requirements to 
        ensure timely delivery and consistent availability of the drug supplies.<o:p></o:p></span></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">This Memorandum of Understanding hereby sets 
        forth the mutual understanding of The Max Foundation and qualified 
        institutions/physicians. <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt">The Max 
        Foundation agrees to:<o:p></o:p></span></b></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;mso-list:l5 level1 lfo2;
tab-stops:list .5in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">1.0<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><u><span style="font-size:11.0pt">GIPAP 
        ADMINISTRATION<o:p></o:p></span></u></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Process all GIPAP patient applications, including performing evaluations 
        of patient socio-economic eligibility, submitted by the qualified physician, 
        institution or TMF representative, within 5 business days of receipt of 
        completed application and all pertinent information (including documents that 
        support patient eligibility);<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Provide patient re-evaluation reminder notices in order to support GIPAP 
        physicians, TMF representatives, and patients with timely patient re-evaluation, 
        with the goal of preventing interruption of Glivec treatment unless medically 
        prescribed;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Develop and maintain a patient tracking system available to support 
        qualified physicians <span style="mso-spacerun:yes">&nbsp;</span>for submitting 
        patient applications to GIPAP, for patient evaluation and approval process, 
        patient re-evaluation, and patient treatment follow-up;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;mso-prop-change:
lschneider 20040414T1641">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.4<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Comply with current standards regarding the protection of confidential 
        patient information and shall treat any information received from patients, TMF 
        representatives and/or third party agencies or physicians, including patient 
        names and confidential medical information, as strictly confidential and shall 
        not disclose such information to any third party except its employees and 
        affiliates who need to know the same for the purpose of administering the terms 
        of this MOU;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;mso-prop-change:
lschneider 20040414T1645">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.5<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Facilitate the reporting of Adverse Events (AE’s) as directed by 
        regulatory authorities in order to assure the highest standards of health and 
        safety for all GIPAP patients (see also section 6.0 Adverse Event Reporting);<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;mso-prop-change:
lschneider 20040414T1645">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">1.6<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Facilitate communications with GIPAP qualified institutions and 
        physicians regarding program updates and other pertinent health and safety 
        information to facilitate the proper management of the program;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-align:left;
text-indent:-.5in">
        <span style="font-size:11.0pt">1.7<span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Provide local assistance, emotional, 
        informational and referral support for patients.<span style="mso-spacerun:yes">&nbsp;
        </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <u><span style="font-size:11.0pt"><o:p><span style="text-decoration:none">&nbsp;</span></o:p></span></u></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt">The 
        <st1:personname
w:st="on">GIPAP</st1:PersonName> Qualified Institution/Physician agrees to:<o:p></o:p></span></u></b></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 31.5pt">
        <span style="font-size:11.0pt">2.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>APPLICATION &amp; APPROVAL PROCESS</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 46.35pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">2.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>On behalf of CML or GIST patients, complete and submit the GIPAP 
        application to The Max Foundation (TMF). Qualified physicians from your 
        institution who are interested in applying for GIPAP on behalf of their patients 
        can obtain an application from <a href="http://www.maxaid.org/">www.maxaid.org</a>.<span 
            style="mso-spacerun:yes">&nbsp; </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 1.0in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">2.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Once a GIPAP application is submitted on behalf of a patient TMF 
        validates the application and notifies the patient and physician within five 
        days of receiving all pertinent information (including documents that support 
        eligibility) whether the patient is approved under the GIPAP criteria.<span 
            style="mso-spacerun:yes">&nbsp; </span>If the patient is approved, 120-day 
        supplies of Glivec will be issued to the patient’s physician at no cost.<span 
            style="mso-spacerun:yes">&nbsp; </span>For every new patient, positive 
        laboratory results for CML (<st1:place w:st="on"><st1:city w:st="on">Philadelphia</st1:City></st1:place>
        chromosome) and GIST (CD 117) are to be reported to TMF at the start of 
        treatment; <b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span>
    </p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 1.0in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">2.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>To remain in the program, a patient eligibility evaluation must be filed 
        with TMF at least 30 days before the current prescription expires or 60 days 
        after the last approval. <b style="mso-bidi-font-weight:normal"><o:p></o:p></b>
        </span>
    </p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt">
        <span style="font-size:11.0pt">3.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>CONSENT &amp; PATIENT SOCIO-ECONOMIC REVIEW </u><o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt">
        <span style="font-size:11.0pt">3.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span style="color:black">The Qualified Institution will obtain the 
        written consent of the patient at the time of application to GIPAP, including 
        the patient’s willingness to inform about health related and/or financial 
        changes. The patient will receive a copy of the signed GIPAP consent form as 
        provided by Novartis;<o:p></o:p></span></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt">
        <span style="font-size:11.0pt;color:black"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt">
        <span style="font-size:11.0pt;color:black">3.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Upon TMF request and/or in cooperation with TMF or a third party, the 
        Qualified Institution will document and evaluate the socio-economic status of 
        the patient in accordance with <st1:personname w:st="on">GIPAP</st1:PersonName> 
        guidelines established by Novartis.</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt">
        <span style="font-size:11.0pt">4.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;
        </span><u>MEDICAL PERSONNEL, DIAGNOSTIC, &amp; LABORATORY SERVICES</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:27.0pt;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.0pt">
        <span style="font-size:11.0pt">4.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician will have licensed medical doctors 
        who are qualified hematology or cancer specialists and able to provide expert 
        opinion on the indication and the approved GIPAP patient’s response to therapy;<o:p></o:p></span></p>
    <p class="MsoHeader" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
.5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.1pt;mso-list:l1 level2 lfo3;
tab-stops:list 1.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.2<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The Qualified 
        Institution/Physician will provide basic diagnostic and laboratory services to 
        ensure patient follow-up. The institution will also be encouraged to have the 
        capacity to test for <st1:place w:st="on"><st1:city w:st="on">Philadelphia</st1:City></st1:place>
        chromosome and diagnose GIST; otherwise, the tests must be done by an 
        institution that has this capacity; <o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:26.9pt;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.1pt;mso-list:l1 level2 lfo3;
tab-stops:list 1.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.3<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">When The Qualified 
        Institution/Physician has the capacity to test for <st1:place w:st="on">
        <st1:city
 w:st="on">Philadelphia</st1:City></st1:place> chromosome and diagnose GIST, or can 
        collaborate with an institution having this capacity, the institution will be 
        able to serve as a referral center for patients with suspicion of CML or GIST;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.1pt;mso-list:l1 level2 lfo3;
tab-stops:list 1.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.4<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The Qualified 
        Institution/Physician agrees to allow TMF or designated TMF local representative 
        to provide the Qualified Institution/Physician’s contact information to patients 
        and/or caregivers for the purposes of medical referral to the GIPAP qualified 
        institution.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;</span><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt">5.0<span style="mso-tab-count:1">&nbsp; </span>
        <u>TAX &amp; CUSTOMS/ PURPOSE &amp; CARE OF DONATION</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-64.9pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>5.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician will obtain tax and customs 
        exemptions (upon Novartis <st1:personname w:st="on">CPO</st1:PersonName>
        or Axios request), store the drug donation <i style="mso-bidi-font-style:normal">
        (see sec. 7.3),</i> and dispense the appropriate dose and quantity to 
        individually approved GIPAP patients, with the exception of regions where a 
        central drug stockist dispenses Glivec to patients approved in GIPAP;<o:p></o:p></span></p>
    <p class="MsoHeader" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
.5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-43.65pt">
        <span style="font-size:11.0pt">5.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician understands, agrees, and confirms 
        that the donation is intended to enable patients diagnosed in
        <span style="mso-bidi-font-style:
italic">your country,</span> for an approved indication of Glivec, to have access to 
        Glivec for the treatment of a life-threatening disease.<span 
            style="mso-spacerun:yes">&nbsp; </span>The institution shall use Glivec only 
        for the purposes of delivering Glivec to the patients approved under GIPAP.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
1.0in;mso-layout-grid-align:none;text-autospace:none">
        <span style="font-size:
11.0pt;color:black"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt">6.0<span style="mso-tab-count:1">&nbsp; </span>
        <u>ADVERSE EVENT REPORTING</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-64.9pt;tab-stops:27.0pt;
mso-layout-grid-align:none;text-autospace:none">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>6.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span style="color:black">The Qualified Institution/Physician should 
        report adverse events as required by their national legislation;<o:p></o:p></span></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-64.9pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt"><span style="mso-tab-count:2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.0pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">6.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Novartis has local Novartis Country Pharma Organizations (<st1:personname 
            w:st="on">CPO</st1:PersonName>’s) and <span style="color:black">the 
        information can</span> be reported to the Novartis <st1:personname w:st="on">CPO</st1:PersonName>’s 
        Drug Safety and Epidemiology Desk. The form shall be sent by fax to the number 
        provided by Novartis;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.0pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 1.0in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-45.0pt;tab-stops:list 1.0in">
        <span style="font-size:11.0pt">6.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>As noted in section 1.5, TMF will facilitate the reporting of Adverse 
        Events (AE’s) in order to assure the highest standards of health and safety for 
        all GIPAP patients.<span style="mso-spacerun:yes">&nbsp; </span>This means that 
        TMF will report to Novartis all AEs that they learn of through the participation 
        of a patient in the GIPAP program regardless of the seriousness or suspectedness 
        of the event.<span style="mso-spacerun:yes">&nbsp; </span>This reporting is 
        separate from the local reporting obligation that physicians must adhere to 
        based on their local reporting requirements.<span style="mso-spacerun:yes">&nbsp;
        </span>Novartis will direct all follow-up questions to the GIPAP physician 
        (including for reports received from patients and/or caregivers) and will submit 
        AE reports to Health Authorities as required.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold">7.0<span style="mso-tab-count:
1">&nbsp; </span><u>DRUG ACCOUNTABILITY</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-64.9pt;tab-stops:list 27.0pt">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold">
        <span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>7.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician shall follow these instructions r</span><span 
            style="font-size:11.0pt">egarding leftover drugs; <o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 27.0pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-indent:
27.0pt">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold">7.2<span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Drugs remaining with the patient:<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:42.55pt;margin-bottom:.0001pt">
        <span style="font-size:11.0pt;
mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">7.2.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;
        </span>The patient‘s family shall be requested to bring leftover drugs back to 
        the physician;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 1.5in">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>7.2.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp; </span>Physician 
        shall be asked to return leftover drugs to Novartis or have the leftover drugs 
        destroyed by the Qualified Institution/Physician;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 56.7pt">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>7.2.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp; </span>Due to Good 
        Manufacturing Practices (GMP) and regulatory compliance reasons, GIPAP drugs 
        cannot be redispensed and must be destroyed when coming back from a patient;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 56.7pt">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>7.2.4<span style="color:black"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician shall keep supporting documentation 
        of the performed destruction of returned leftover drugs for inspection by 
        Novartis.</span><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;tab-stops:
list 61.1pt">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold">7.3<span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Drugs remaining in physician‘s office: <o:p></o:p>
        </span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:24.55pt;margin-bottom:.0001pt">
        <span style="font-size:11.0pt;
mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 70.9pt">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>7.3.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp; </span>The 
        physician shall be asked to return the drugs kept under their own area of 
        responsibility (i.e., Never delivered to the patient) to the Qualified 
        Institution or to Novartis;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 70.9pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 70.9pt">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;</span><span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp; </span>7.3.2<span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp; </span>The Qualified Institution 
        shall be asked to provide written documentation for the following requirements:<o:p></o:p></span></p>
    <p class="MsoNormal" 
        style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-14.2pt;tab-stops:list 70.9pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:2.0in;margin-bottom:.0001pt;text-indent:-.25in;mso-list:l6 level1 lfo1;
tab-stops:list 2.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol">
        <span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">Product 
        identification:<span style="mso-spacerun:yes">&nbsp; </span>Drug name, Batch 
        number, Expiration date, Patient ID number, Drug quantity; <o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:2.0in;margin-bottom:.0001pt;text-indent:-.25in;mso-list:l6 level1 lfo1;
tab-stops:list 2.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol">
        <span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">Drug product is in 
        its original non-opened container or shipping carton;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:2.0in;margin-bottom:.0001pt;text-indent:-.25in;mso-list:l6 level1 lfo1;
tab-stops:list 2.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol">
        <span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">Individual drug 
        packs have the original closure;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:2.0in;margin-bottom:.0001pt;text-indent:-.25in;mso-list:l6 level1 lfo1;
tab-stops:list 2.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol">
        <span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The 
        container/shipping carton of drug packs are intact, not damaged, dirty, or 
        spoiled.<span style="mso-spacerun:yes">&nbsp; </span>There is no evidence of 
        manipulation (100% inspection must be performed. Random is not allowed);<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:2.0in;margin-bottom:.0001pt;text-indent:-.25in;mso-list:l6 level1 lfo1;
tab-stops:list 2.0in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol">
        <span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The drug product 
        has not been subject to adverse storage or transport conditions.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-.5in;mso-list:l2 level3 lfo4;
tab-stops:list 1.5in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">7.3.3<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">If the remaining 
        shelf life is OK, the drugs are to be used for the next approved patient;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-.5in;mso-list:l2 level3 lfo4;
tab-stops:list 1.5in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">7.3.4<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">If the remaining 
        shelf life is not OK, the drugs are to be destroyed by The Qualified 
        Institution;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-.5in;mso-list:l2 level3 lfo4;
tab-stops:list 1.5in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">7.3.5<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The Qualified 
        Institution shall keep supporting documentation of the performed destruction for 
        inspection by Novartis.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 56.7pt">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 56.7pt">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.5in;margin-bottom:.0001pt;text-indent:-51.3pt;tab-stops:list 56.7pt">
        <span style="font-size:11.0pt;color:black"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:13.5pt;margin-bottom:.0001pt;line-height:13.5pt;tab-stops:list .5in">
        <span style="font-size:11.0pt">8.0<span style="mso-tab-count:1">&nbsp;&nbsp;
        </span><u>RECORD KEEPING</u><span style="mso-tab-count:1">&nbsp; </span><o:p></o:p>
        </span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
13.5pt;tab-stops:list .5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="font-size:11.0pt"><span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>8.1<span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The 
        Qualified Institution/Physician shall keep detailed GIPAP records including: the 
        number of GIPAP patients using Glivec, patients’ Glivec treatment schedule, 
        patient’s name &amp; GIPAP personal ID number (PIN) (available from GIPAP approval 
        notification), diagnostic test results confirming approved indication for 
        Glivec, and signed patient consent form; <o:p></o:p></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="font-size:11.0pt"><span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>8.2<span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The 
        Qualified Institution/Physicians shall maintain socio-economic evaluation and/or 
        supporting socio-economic documents if requested by TMF;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;</span><a 
            name="OLE_LINK1"><o:p></o:p></a></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt">
        <span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>8.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician shall facilitate and keep record of 
        patient’s access to GIPAP where patients meet the GIPAP eligibility criteria set 
        forth by Novartis and outlined in this Memorandum of Understanding;<span 
            style="mso-spacerun:yes">&nbsp; </span><o:p></o:p></span></span>
    </p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt">
        <span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>8.4<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Should the institution wish to collect data for the purpose of conducting 
        investigator initiated protocols or research studies involving GIPAP patients 
        and/or the GIPAP process, the institution shall first obtain written permission 
        from Novartis;<o:p></o:p></span></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;line-height:13.5pt;
tab-stops:list .5in">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt">
        <span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>8.5<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution shall keep detailed drug accountability records
        <i style="mso-bidi-font-style:normal">(see sec. 7.3.2 and sec. 7.3.5) </i>except 
        in regions where drug supply and distribution is maintained by a central 
        stockist.<o:p></o:p></span></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
13.5pt;tab-stops:list .5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoBodyTextIndent" style="margin-left:.25in;text-indent:-.25in;
mso-list:l0 level1 lfo5;tab-stops:list .5in">
        <![if !supportLists]>
        <span style="font-size:11.0pt;mso-fareast-font-family:Arial">
        <span style="mso-list:
Ignore">9.0<span style="font:7.0pt &quot;Times New Roman&quot;">&nbsp; </span></span>
        </span><![endif]><u><span style="font-size:11.0pt">CONFIDENTIALITY &amp; 
        COMMUNICATIONS<o:p></o:p></span></u></p>
    <p class="MsoBodyTextIndent" style="margin-top:6.0pt;margin-right:0in;margin-bottom:
6.0pt;margin-left:1.0in;text-indent:-.5in">
        <span style="font-size:11.0pt">9.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician shall keep confidential the terms and 
        conditions of this Memorandum of Understanding (MOU); <o:p></o:p></span>
    </p>
    <p class="MsoBodyTextIndent" style="margin-top:6.0pt;margin-right:0in;margin-bottom:
6.0pt;margin-left:1.0in;text-indent:-.5in">
        <span style="font-size:11.0pt">9.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution/Physician will comply with all local laws 
        including the protection of confidential patient information.<span 
            style="mso-spacerun:yes">&nbsp; </span>The Qualified Institution/Physician 
        shall treat any information received from the patients, including patient names 
        and confidential medical information, as strictly confidential and shall not 
        disclose such information to any third party except its employees who need to 
        know the same for the purpose of administering the terms of this MOU and The Max 
        Foundation and their locally appointed representatives for similar purposes;<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent" style="margin-top:6.0pt;margin-right:0in;margin-bottom:
6.0pt;margin-left:1.0in;text-indent:-.5in">
        <span style="font-size:11.0pt">9.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Qualified Institution shall treat any information received from The 
        Max Foundation and Novartis as strictly confidential and shall not disclose such 
        information to any third party except its employees who need to know the same 
        for the purpose of administering the terms of this MOU.<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent3" style="margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">10.0<span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp; </span><u>LOCAL NOVARTIS AFFILIATE &amp; AXIOS</u></span><u><span 
            style="font-size:11.0pt"><o:p></o:p></span></u></p>
    <p class="MsoBodyTextIndent3" style="margin-top:8.0pt;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;
tab-stops:.5in">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>10.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp; </span>Local 
        Novartis Affiliate (Or Axios where applicable) shall inform the Ministry of 
        Health and key partners in your country about GIPAP;<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent3" style="margin-top:8.0pt;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;
tab-stops:1.0in">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
        &nbsp;&nbsp;&nbsp;</span>10.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp; </span>
        Local Novartis Affiliate (Or Axios where applicable) shall provide a donation 
        certificate to enable The Qualified Institution/Physicians to obtain tax and 
        customs related exemptions on the drugs where relevant;<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent3" style="margin-top:8.0pt;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;
tab-stops:.5in">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>10.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp; </span>Local 
        Novartis Affiliate (Or Axios where applicable) shall order Glivec and send 
        shipment to The Qualified Institution/Physician based on approved requests; <o:p></o:p>
        </span>
    </p>
    <p class="MsoBodyTextIndent3" style="margin-top:8.0pt;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-indent:-1.0in;
tab-stops:.5in">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>10.4<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp; </span>Local 
        Novartis Affiliate (Or Axios where applicable) shall maintain an ongoing 
        dialogue with the GIPAP Qualified Institution about progress made and obstacles 
        encountered.<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent3" style="margin-top:8.0pt;margin-right:0in;
margin-bottom:0in;margin-left:13.5pt;margin-bottom:.0001pt;text-indent:-13.5pt;
tab-stops:.5in">
        <span style="font-size:11.0pt">11.0<span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp; </span><u>AUDITS &amp; TERMINATION</u><o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-.5in">
        <span style="font-size:11.0pt">11.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Max Foundation, Novartis (and/or its affiliates), or an auditor 
        appointed by TMF or Novartis, shall be entitled to audit The Qualified 
        Institution/Physician; such audits shall be conducted in line with local laws 
        including privacy laws;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">11.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>If improper use of Glivec is found, TMF or Novartis reserves all rights 
        to terminate GIPAP to The Qualified Institution/Physician;<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-indent:-.5in">
        <span style="font-size:11.0pt">11.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Either party may terminate this MOU by notice to the other at least 30 
        days in advance of the termination date.<o:p></o:p></span></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt">
        <b><span style="font-size:11.0pt">IN WITNESS WHEREOF</span></b><span style="font-size:
11.0pt">, the parties have caused this MOU to be executed by their duly authorized 
        officers or representatives.<o:p></o:p></span></p>
   
</body>
</html>
